DiaMedica Therapeutics (DMAC) Cash from Financing Activities (2018 - 2026)

DiaMedica Therapeutics (DMAC) has reported Cash from Financing Activities for 9 consecutive years, with $132000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash from Financing Activities fell 18.01% year-over-year to $132000.0; the trailing twelve-month figure through Jun 2026 stood at $44.2 million (up 8823.84% YoY), and the FY2025 full-year result was $43.9 million, up 265.82% from the prior year.
• Cash from Financing Activities fell to $132000.0 in Q2 2026 per DMAC's latest filing, from $417000.0 in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $36.8 million in Q2 2023 and bottomed at -$6000.0 in Q3 2023.
• Historically, Cash from Financing Activities has averaged $5.2 million across 5 years, with a median of $105500.0 in 2024.
• The widest YoY moves for Cash from Financing Activities: up 1842600.0% in 2023, down 200.0% in 2023.
• Over 5 years, Cash from Financing Activities stood at -$1000.0 in 2022, then changed by 0.0% to -$1000.0 in 2023, then surged by 12100.0% to $120000.0 in 2024, then soared by 9975.83% to $12.1 million in 2025, then tumbled by 98.91% to $132000.0 in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $132000.0, $417000.0, and $12.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.